【摘要】：目的探討干擾素聯(lián)合阿德福韋酯治療對拉米夫定耐藥乙型肝炎患者的臨床效果,為臨床效果提供理論指導與依據(jù)。方法選取2011年2月-2013年2月于醫(yī)院接受治療的90例對拉米夫定耐藥乙型肝炎患者作為研究對象,隨機平均分為對照組和觀察組,各45例;對照組患者應用阿德福韋酯進行治療,觀察組患者應用干擾素聯(lián)合阿德福韋酯進行治療;比較兩組患者治療12個月后的臨床指標,數(shù)據(jù)采用SPSS 10.0軟件進行統(tǒng)計分析。結(jié)果對照組患者治療前后丙氨酸氨基轉(zhuǎn)移酶、HBV-DNA與觀察組比較,差異均無統(tǒng)計學意義;對照組患者的HBsAg和HBeAg陰轉(zhuǎn)率分別為0和42.86%,觀察組患者的HBsAg和HBeAg陰轉(zhuǎn)率分別為9.38%和91.67%,觀察組患者的陰轉(zhuǎn)率顯著高于對照組的,差異有統(tǒng)計學意義(P0.05)。結(jié)論兩組治療方法對患者均起到了治療的作用,聯(lián)合治療比單使用阿德福韋酯治療的效果更好,能更好、更快提高患者HBeAg和HBsAg的陰轉(zhuǎn)率。
[Abstract]:Objective to investigate the clinical effect of interferon combined with adefovir in lamivudine resistant hepatitis B patients, and to provide theoretical guidance and basis for clinical effect. Methods from February 2011 to February 2013, 90 patients with lamivudine resistant hepatitis B were randomly divided into control group and observation group. The patients in the control group were treated with adefovir ester, the patients in the observation group were treated with interferon and adefovir ester, and the clinical indexes of the two groups were compared after 12 months of treatment. The data were analyzed by SPSS 10.0 software. Results there was no significant difference in alanine aminotransferase and HBV-DNA between the control group and the observation group before and after treatment. The negative conversion rates of HBsAg and HBeAg were 0 and 42.86 in the control group, and 9.38% and 91.67% in the observation group, respectively. The negative conversion rate of the observation group was significantly higher than that of the control group. The difference was statistically significant (P0.05). Conclusion both the two groups have a therapeutic effect on the patients. The combined treatment is better and better than that of adefovir alone, and the negative conversion rate of HBeAg and HBsAg can be increased more quickly than that of adefovir alone.
【作者單位】： 寧夏人民醫(yī)院感染病科;陜西醫(yī)科大學附屬第一醫(yī)院;
【基金】：寧夏自然科學基金資助項目(NZ1271)
【分類號】：R512.62
，

本文編號：2365797